Tag: sofosbuvir

1. From a computer simulation, sofosbuvir-based regimens may be more cost-effective in patients with cirrhosis or previously treated with interferon. Evidence Rating Level: 2 (Good) Study Rundown: In 2013, the U.S. Food and Drug Administration (FDA) approved sofosbuvir, a nucleotide analog that inhibits viral RNA synthesis in combination with ribavirin for...
In this section, we highlight the key high-impact studies, updates, and analyses published in medicine during the past week. Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events Proportein convertase subtilisin-kexin type 9 (PCSK9) plays an important role in the recycling and regulation of low-density lipoprotein (LDL) receptors. Monoclonal...
1. Sofosbuvir plus ledipasvir was effective in treating chronic hepatitis C virus (HCV) genotype 1 infection in patients who were not candidates for interferon and who suffered viral relapse after prior sofosbuvir-based treatment. Evidence Rating Level: 2 (Good) Study Rundown: Sofosbuvir, an NS5B inhibitor, is an alternative to interferon-based...
1. : Simeprevir plus sofosbuvir achieved high sustained virological response 12 weeks after stopping treatment (SVR12) in patients with chronic HCV genotype 1 infections.  2. : Daclatasvir plus asunaprevir achieved high SVR12 in patients with chronic HCV genotype 1b infections.  Evidence Rating Level: 1 (Excellent)  Study Rundown: Hepatitis C infection is associated...
1. A 12 to 24 week regimen of sofosbuvir and ribavirin induced a sustained viral response in hepatitis C (HCV) patients co-infected with HIV.  2. No significant adverse effects from sofosbuvir were observed during this phase 3 trial.  Evidence Rating Level:  2 (Good)            Study Rundown: Until recently,...
Image: PD 1. A single-tablet regimen of ledipasvir and sofosbuvir produced high rates of sustained virologic response among patients with chronic hepatitis C virus genotype 1 infection who had previously failed conventional interferon therapy.  2. No patient discontinued therapy due to an adverse event.  Evidence Rating Level: 1 (Excellent)       Study...
Image: PD In this section, we will highlight the key high-impact studies, updates, and analyses published in medicine during the past week. Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection The current FDA-approved regimen for treatment of Hepatitis C (HCV) genotype 1...
Image: PD In this section, we will highlight the key high-impact studies, updates, and analyses published in medicine during the past week. Dolutegravir Plus Abacavir-Lamivudine for the Treatment of HIV-1 Infection Antiretroviral therapy in the treatment of human immunodeficiency virus (HIV) infection has dramatically improved the survival of HIV-positive patients, but traditional...
Image: PD 1. The addition of sofosbuvir to peginterferon-ribavirin was effective at achieving sustained virologic response against HCV genotypes 1, 4, 5 and 6. For HCV genotypes 2 and 3, sofosbuvir and ribavirin was non-inferior to current treatment (peginterferon-ribavirin).  2. Patients treated with sofosbuvir experienced fewer adverse events overall.  Evidence Rating Level:...